Trial Profile
A Phase II Study of Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Brigatinib (Primary)
- Indications Anaplastic large cell lymphoma
- Focus Therapeutic Use
- 04 Jan 2021 Planned End Date changed from 1 Dec 2021 to 16 Jun 2020.
- 04 Jan 2021 Planned primary completion date changed from 1 Dec 2020 to 18 Mar 2020.
- 04 Jan 2021 Status changed from recruiting to withdrawn prior to enrolment.